Reduction in respiratory mortality not associated with influenza in
  Russia: effect of the introduction of pneumococcal vaccination (PCV13), or
  improvement in care? by Goldstein, Edward
Reduction	in	respiratory	mortality	not	associated	with	influenza	in	Russia:	effect	of	the	introduction	of	pneumococcal	vaccination	(PCV13),	or	improvement	in	care?		Edward	Goldstein1,*		 1. Center	for	Communicable	Disease	Dynamics,	Department	of	Epidemiology,	Harvard	TH	Chan	School	of	Public	Health,	Boston,	MA	02115	USA		*.				egoldste@hsph.harvard.edu			
Abstract		
Background.	Pneumococcal	vaccination	(PCV13)	for	children	(as	well	as	older	adults)	in	Russia	was	introduced	in	2014,	with	no	prior	PCV7	use.	While	pneumonia	hospitalization	rates,	both	in	children	and	adults	didn’t	decrease	in	the	following	years,	respiratory	mortality	rates	did	decline	with	time.	Moreover,	there	is	a	strong	association	between	antibiotic,	including	multidrug	resistance	and	PCV13	vaccine	serotypes	for	S.	pneumoniae	in	children	in	Russia,	and	presence	of	S.	pneumoniae	among	sepsis	cases	in	Russia	during	the	recent	years	has	been	very	low.	Annual	variability	in	influenza	circulation	may	affect	some	of	the	changes	in	respiratory	mortality	rates,	obscuring	the	trends	in	respiratory	mortality	related	to	pneumococcal	vaccination.	
Methods.	We	applied	the	inference	method	from	our	recent	study	of	influenza-associated	mortality	in	Russia	to	relate	monthly	respiratory	mortality	rates	between	09/2010	and	08/2019	to	monthly	indices	of	influenza	circulation	and	baseline	rates	of	mortality	not	associated	with	influenza,	allowing	for	a	potential	trend	in	the	baseline	rates	starting	2015.	
Results.	Baseline	rates	of	respiratory	mortality	not	associated	with	influenza	decreased	with	time	starting	from	the	2014/15	season	(with	each	season	running	
from	September	to	August),	with	the	2018/19	baseline	rates	of	respiratory	mortality	per	100,000	individuals	being	lower	by	12.41	(95%	CI	(10.6,14.2))	compared	to	the	2010-2014	period.	
Conclusions.	While	improvement	in	care	might	have	contributed	to	the	reduction	in	the	rates	of	respiratory	mortality	not	associated	with	influenza	in	Russia,	the	above	temporally	consistent	reduction	is	compatible	with	the	gradual	replacement	of	vaccine	serotypes	in	the	transmission	and	carriage	of	S.	pneumoniae	following	the	introduction	of	PCV13.	Further	work	is	needed	to	better	understand	the	impact	of	PCV13	on	the	epidemiology	of	respiratory	infections	and	related	mortality	in	Russia.		 	
Introduction	
	Pneumococcal	conjugate	vaccine	(PCV13)	was	introduced	in	Russia	in	2014,	with	high	uptake	in	young	children	reported	by	2016	[1].	Serotype	replacement	compared	to	carriage	data	from	the	pre-PCV13	years	was	found	[2-4],	with	serotype	replacement	following	pneumococcal	vaccination	also	having	taken	place	in	other	countries	[5,6].	While	rates	of	pneumonia	following	the	introduction	of	PCV13	in	Russia	have	not	decreased,	neither	in	children	[1],	nor	overall	[7],	one	can	see	a	notable	decline	in	the	rates	of	mortality	for	respiratory	causes	in	the	years	following	the	rollout	of	PCV13	[8].	Some	of	that	decline	may	potentially	be	explained	by	a	strong	association	between	antibiotic,	including	multidrug	resistance	and	PCV13	vaccine	serotypes	[3,4],	with	resistant	infections	with	vaccine	serotypes	(compared	to	non-vaccine	serotypes)	being	more	likely	to	devolve	into	the	most	severe	outcomes,	including	sepsis	and	death.	Indeed,	a	major	study	of	septic	infections	in	St.	Petersburg,	Russia	found	that	respiratory	tract	was	the	most	common	source	of	those	infections,	and	S.	pneumoniae	was	found	very	rarely	for	those	cases	[9].		In	this	study	we	aim	to	evaluate	the	trends	in	respiratory	mortality	rates	in	Russia	following	the	introduction	of	PCV13	vaccination.	Annual	variability	in	influenza	circulation	may	affect	some	of	the	changes	in	respiratory	mortality	rates,	obscuring	
the	above	trends.	For	example,	the	rate	of	respiratory	mortality	in	Russia	during	the	2014/15	season	(September	through	August)	was	higher	than	during	each	of	the	four	previous	seasons	(2010/11	through	2013/14),	with	that	difference	being	related	to	the	mortality	associated	with	the	major	2014/15	influenza	season	[10].	Thus,	in	order	to	study	trends	in	respiratory	(or	pneumonia)	mortality	rates,	one	ought	to	adjust	the	observed	rates	for	the	effect	of	influenza	circulation.	Here,	we	apply	the	inference	methodology	from	our	recent	study	of	influenza-associated	mortality	in	Russia	[10]	to	relate	the	monthly	rates	of	respiratory	mortality,	provided	by	the	Russian	Federal	State	Statistics	Service	(Rosstat)	[8]	to	the	indices	of	monthly	incidence	of	influenza	A/H3N2,	A/H1N1,	and	B	in	Russia	(derived	from	the	surveillance	data	from	the	Smorodintsev	Research	Institute	of	Influenza	(RII)	[11]),	adjusting	for	baseline	rates	of	respiratory	mortality	not	associated	with	influenza.	Moreover,	we	include	terms	for	the	trend	in	baseline	rates	of	non-influenza	associated	respiratory	mortality	to	examine	the	change	in	those	rates	following	the	introduction	of	PCV13.	We	also	discuss	the	potential	causes	for	the	changes	in	respiratory	mortality	rates,	including	the	effect	of	pneumococcal	vaccination.			
Methods		
Data	Monthly	data	on	mortality	for	respiratory	causes	in	Russia	were	obtained	from	[8].	Monthly	mortality	counts	for	respiratory	deaths	were	then	converted	to	monthly	rates	of	mortality	per	100,000	individuals	using	population	data	from	Rosstat	(with	annual	population	estimates	interpolated	linearly	to	estimate	the	population	by	month).		Weekly	data	on	the	rates	of	influenza/Acute	Respiratory	Illness	(ARI),	(грипп/ОРВИ)	consultation	per	10,000	individuals	in	Russia	are	available	from	[11].	Data	on	the	weekly	percent	of	respiratory	specimens	from	symptomatic	
individuals	that	were	RT-PCR	positive	for	influenza	A/H1N1,	A/H3N2	and	influenza	B	are	also	available	from	[11]	(under	the	Laboratory	Diagnostics	link).			Incidence	proxies	Only	a	fraction	of	individuals	presenting	with	influenza/ARI	symptoms	are	infected	with	influenza.	We	multiplied	the	weekly	rates	of	influenza/ARI	consultation	per	10,000	individuals	[11]	by	the	weekly	percentages	of	respiratory	specimens	from	symptomatic	individuals	that	were	RT-PCR	positive	for	each	of	influenza	A/H1N1,	A/H3N2	and	B	[11]	to	estimate	the	weekly	incidence	proxies	for	each	of	the	corresponding	influenza	(sub)types:			
Weekly	influenza	(sub)type	incidence	proxy	=																																												(1)	
Rate	of	consultations	for	influenza/ARI	*	%	All	respiratory	specimens	that	were	RT-
PCR	positive	for	that	influenza	(sub)type		As	noted	in	[12],	those	proxies	are	expected	to	be	proportional	to	the	weekly	population	incidence	for	the	each	of	the	major	influenza	(sub)types	(hence	the	name	“proxy”)	–	in	fact,	those	proxies	estimate	the	weekly	rates	of	consultation	for	ARI	associated	with	the	corresponding	influenza	(sub)types,	divided	by	the	sensitivity	of	the	RT-PCR	test.	Monthly	incidence	proxies	for	influenza	A/H1N1,	A/H3N2	and	B	were	obtained	as	the	weighted	average	of	the	weekly	incidence	proxies	for	those	weeks	that	overlapped	with	a	given	month;	specifically,	for	each	influenza	(sub)type	and	month,	the	incidence	proxy	for	each	week	was	multiplied	by	the	number	of	days	in	that	week	that	were	part	of	the	corresponding	month	(e.g.	7	if	the	week	was	entirely	within	that	month),	then	the	results	were	summed	over	the	different	weeks	and	divided	by	the	number	of	days	in	the	corresponding	month.	To	relate	the	incidence	proxies	for	the	major	influenza	(sub)types	to	monthly	mortality	rates,	we	first	shift	the	weekly	incidence	proxies	by	one	week	forward	to	accommodate	for	the	delay	between	infection	and	death	[12],	then	use	the	shifted	weekly	incidence	proxies	to	obtain	the	corresponding	monthly	incidence	proxies	as	above.			
The	relation	between	an	incidence	proxy	and	the	associated	mortality	may	change	over	time.	In	particular,	influenza	B	is	characterized	by	the	circulation	of	
B/Yamagata	and	B/Victoria	viruses.	It	is	known	that	the	age	distribution	for	the	
B/Yamagata	infections	is	notably	older	than	for	the	B/Victoria	infections	[13,14].	Correspondingly,	the	relation	between	the	incidence	proxy	(which	reflects	influenza	incidence	in	the	general	population)	and	influenza-related	mortality	(which	for	influenza	B	largely	reflects	mortality	in	older	individuals)	may	be	quite	different	for	influenza	B/Yamagata	compared	to	influenza	B/Victoria.	While	there	are	no	data	on	the	weekly	percentages	of	B/Yamagata	and	B/Victoria	among	the	tested	respiratory	specimens	in	[11],	such	whole-season	data	are	available	in	[11].	For	each	influenza	season	(running	from	September	to	June),	we	obtain	the	proportions	of	influenza	B	specimens	from	that	season	that	were	for	B/Yamagata	and	B/Victoria	(using	data	from	the	last	reported	week	during	that	season	[11]),	and	multiply	the	weekly	incidence	proxy	for	influenza	B	during	that	season	by	the	corresponding	proportions	to	estimate	the	weekly	incidence	proxy	for	each	of	influenza	
B/Yamagata	and	B/Victoria.	Finally,	the	2014/15	season	was	characterized	by	the	global	circulation	of	a	novel	A/H3N2	variant.	Mortality	for	that	variant	is	potentially	different	from	the	mortality	for	the	previously	circulating	A/H3N2	strains.	Correspondingly,	to	relate	A/H3N2	to	respiratory	mortality,	we	split	the	A/H3N2	incidence	proxy	into	two:	one	(called	𝐴/𝐻3𝑁2!) equaling	the	A/H3N2	proxy	between	09/2010	through	08/2014,	zero	for	subsequent	months;	the	other	(called	𝐴/𝐻3𝑁2!) equaling	the	A/H3N2	proxy	between	09/2014	through	08/2019,	zero	for	previous	months.	Figure	1	plots	the	monthly	incidence	proxies	for	influenza	A/H3N2	(two	proxies),	A/H1N1,	B/Yamagata	and	B/Victoria	between	09/2010	and	08/2019	(108	months).		
Inference	Model	Let	𝑀(𝑡)	be	the	average	daily	respiratory	mortality	rate	per	100,000	during	month	𝑡 	(with	𝑡 = 1	for	09/2010,	𝑡 = 108		for	08/2019),	and	𝐴/𝐻3𝑁2!(𝑡),𝐴/𝐻3𝑁2!(𝑡),𝐴/𝐻1𝑁1(𝑡),𝐵/𝑉𝑖𝑐𝑡𝑜𝑟𝑖𝑎(𝑡),𝐵/𝑌𝑎𝑚𝑎𝑔𝑎𝑡𝑎(𝑡)	be	the	incidence	proxies	for	the	different	
influenza	(sub)types	on	month	𝑡	as	described	in	the	previous	subsection.	The	inference	model	in	[10,12]	suggests	that			𝑀 𝑡 = 𝛽! + 𝛽! ∙ 𝐴/𝐻3𝑁2!(𝑡)+ 𝛽! ∙ 𝐴/𝐻3𝑁2!(𝑡)+ 𝛽! ∙ 𝐴/𝐻1𝑁1(𝑡)+ 𝛽! ∙ 𝐵/𝑉𝑖𝑐𝑡𝑜𝑟𝑖𝑎(𝑡)+ 𝛽! ∙  𝐵/𝑌𝑎𝑚𝑎𝑔𝑎𝑡𝑎(𝑡)+ 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 +  𝑁𝑜𝑖𝑠𝑒																(2)	
	Here	the	noise	is	white	noise	(linear	regression),	and	𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒	is	the	baseline	average	daily	rate	of	respiratory	mortality	per	100,000	not	associated	with	influenza	circulation.	We	assume	that	this	rate	is	periodic	with	yearly	periodicity,	excpet	for	the	potential	trend	starting	2015.	We	will	model	it	as		𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑡 = 𝛽! ∙ cos !!"!" + 𝛽! ∙ sin !!"!"  + 𝛽! ∙ Jan t + SE t + Trend					(3)		Here	𝐽𝑎𝑛	is	a	variable	equaling	1	for	the	month	of	January,	0	otherwise.	The	reason	for	including	this	variable	is	that	the	monthly	(rather	than	annual)	mortality	data	in	[8]	is	operational,	with	some	of	the	mortality	not	registered	during	a	given	calendar	year	being	added	to	January	of	the	next	year	[15].	The	(temporal)	trend	is	modeled	as	a	quadratic	polynomial	in	the	month	starting	01/2015	(thus	the	month	for	the	trend	equals	0	prior	to	01/2015,	it	equals	1	for	01/2015,	it	equals	13	for	01/2016	etc.,	and	the	trend	is	a	quadratic	function	of	that	month).	Finally,	the	summer	effect	SE t 	equals	1	for	the	month	of	July,	2	for	the	month	of	August,	and	0	for	other	months.	The	reason	for	including	this	variable	is	that	there	is	a	consistent	dip	in	respiratory	mortality	(Figure	2)	during	the	months	of	July	and	August	(particularly	August),	presumably	having	to	do	with	the	decline	in	the	transmission	of	respiratory	viruses	when	schools	are	closed/weather	is	hot,	and	this	dip	cannot	be	accommodated	by	the	trigonometric	model	in	eq.	3.	While	this	variable	wasn’t	included	in	the	model	in	[10],	its	inclusion	results	in	a	significant	improvement	in	the	model	fit,	and	excluding	this	variable	has	a	very	minor	effect	on	the	estimation	of	the	trend	in	respiratory	mortality	following	the	introduction	of	PCV13.		
	
Results		Figure	1	plots	the	monthly	proxies	for	the	incidence	of	influenza	A/H3N2	(split	into	two	as	described	in	Methods),	A/H1N1,	B/Yamagata,	and	B/Victoria	during	our	study	period	(09/2010	through	08/2019).		
		
Figure	1:	Monthly	proxies	for	the	incidence	of	influenza	A/H3N2	(split	into	the	09/2010	though	the	08/2104	period	and	the	09/2014	through	the	08/2019	period),	A/H1N1,	B/Yamagata,	and	B/Victoria	between	09/2010	through	08/2019.		
Figure	2	presents	the	fits	for	the	model	in	eq.	2	for	the	average	daily	rates	of	respiratory	mortality	per	100,000	individuals	by	month	(black	curve)	for	the	months	of	09/2010	through	08/2019.	Those	model	fits	were	largely	temporally	consistent	save	for	the	early	part	of	the	study	period,	which	may	partly	have	to	do	with	data	quality	for	that	period	---	see	Discussion.	Figure	2	also	exhibits	the	average	daily	baseline	rates	(by	month)	of	respiratory	mortality	per	100,000	people	not	associated	with	influenza	between	09/2010	though	08/2019.	Those	rates	declined	during	the	period	following	the	introduction	of	PCV13	vaccination.		
	
	
Figure	2:	Average	daily	rates	of	respiratory	mortality	per	100,000	people	by	month	(black	curve);	fits	for	the	model	in	eq.	2	(red	curve);	average	daily	baseline	rates	(by	month)	of	respiratory	mortality	per	100,000	people	not	associated	with	influenza	(green	curve)	between	09/2010	though	08/2019.	
	Table	1	presents	the	estimates	of	the	rates	of	influenza-associated	respiratory	mortality	during	each	of	the	2010/11	through	the	2018/19	seasons	(September	through	August	for	each	season),	as	well	as	the	expected	seasonal	baseline	rates	of	respiratory	mortality	not	associated	with	influenza.	Those	expected	seasonal	rates	were	modeled	as	constant	for	the	2010/11	through	the	2013/14	seasons	(save	for	a	tiny	change	during	the	2011/12	season	due	to	the	fact	that	2012	was	a	leap	year).	Subsequently,	those	baseline	rates	declined,	with	a	decline	of	12.41	(10.6,14.2)	respiratory	deaths	not	related	to	influenza	per	100,000	individuals	during	the	2018/19	season	compared	to	the	2010/11	through	the	2013/14	seasons.		 Season	 Rate	of	influenza-associated	respiratory	mortality	
Expected	rate	of	non-influenza	related	respiratory	mortality	
Reduction	in	respiratory	mortality	rate	following	PCV-13	introduction	2010/11	 2.52	(1.5,3.6)	 49.01	(47.9,50.1)	 	2011/12	 0.08	(-0.8,0.9)	 49.15	(48,50.2)	 	2012/13	 2.76	(1.7,3.8)	 49.01	(47.9,50.1)	 	2013/14	 0.66	(-0.1,1.4)	 49.01	(47.9,50.1)	 	2014/15	 4.43	(3.5,5.4)	 47.87	(46.9,48.9)	 1.14	(0.8,1.5)	2015/16	 2.65	(1.9,3.3)	 44.05	(42.8,45.3)	 5.1	(3.9,6.3)	2016/17	 3.02	(1.6,4.4)	 40.63	(39.3,42)	 8.38	(6.8,9.9)	2018/18	 3.21	(2.6,3.8)	 38.19	(37,39.4)	 10.82	(9.3,12.3)	2018/19	 2.58	(2,3.1)	 36.6	(35,38.2)	 12.41	(10.6,14.2)		
Table	1:	Seasonal	rates	of	influenza-associated	mortality	in	Russia	for	the	2010/11	through	the	2018/19	seasons	(September	through	August),	expected	seasonal	rates	of	non-influenza	associated	respiratory	mortality,	and	reduction	in	non-influenza	associated	mortality	following	the	introduction	of	PCV13	starting	the	2014/15	season.		
	
Discussion	
	The	pneumococcal	conjugate	vaccine	PCV13	was	introduced	in	Russia	in	2014,	with	uptake	increasing	significantly	during	2015	[1].	This	was	followed	by	a	pronounced	decline	in	respiratory	mortality,	including	pediatric	mortality	[1],	though	not	the	rates	of	pneumonia	hospitalization	in	Russia	[1,7].	Some	of	the	reasons	for	the	above	discrepancy	may	have	to	do	with	the	fact	that	vaccine	strains	for	PCV13	are	much	more	drug-resistant,	as	well	as	multidrug-resistant	compared	to	non-vaccine	strains	in	Russia	[3,4].	Influenza	circulation	affects	the	rates	of	respiratory	mortality,	as	well	as	changes	in	those	rates	with	time.	To	better	understand	the	trends	in	respiratory	mortality	not	associated	with	influenza	circulation	in	Russia,	we	applied	the	inference	model	in	[10,12]	to	estimate	the	(baseline)	rates	of	non-influenza	respiratory	mortality,	as	well	as	trends	in	those	baseline	rates.	We	found	a	consistent	decline	in	the	rates	of	non-influenza	respiratory	mortality	starting	2015.	Moreover,	this	finding	was	robust	with	regard	to	several	assumptions	made	in	our	inference	model.		A	key	question	is	related	to	the	causes	behind	the	aforementioned	decline	in	the	rates	of	non-influenza	respiratory	mortality.	Improvement	in	care	could	potentially	contribute	to	decline	in	respiratory	mortality	rates.	At	the	same	time,	changes	in	the	epidemiology	of	pneumococcus,	particularly	reduction	in	the	carriage	of	vaccine-type	strains	in	children	took	place	in	Russia	[2-4].	In	the	US,	virtual	disappearance	of	the	winter	holiday	season	bump	in	pneumonia	mortality	took	place	following	the	introduction	of	the	PCV7	vaccine	(Figure	2	in	[12]),	with	that	bump	prior	to	the	introduction	of	PCV7	ascribed	to	the	transmission	of	pneumococcal	strains	from	young	children	to	their	grandparents	during	the	holiday	season.	In	Russia,	transmission	of	S.	pneumoniae	from	young	children	to	older	individuals	might	be	even	greater	than	in	the	US	due	to	differences	in	contacts	between	those	age	groups	for	the	two	countries.	Additionally,	non-vaccine	strains	of	S.	pneumonia	in	children	in	Russia	are	much	less	antibiotic-resistant	compared	to	vaccine	strains	for	PCV13	
[3,4].	All	of	this	suggests	that	the	decline	in	non-influenza	respiratory	mortality	rates	estimated	in	this	study	is	also	consistent	with	the	replacement	of	vaccine	serotypes	in	the	transmission	and	carriage	of	S.	pneumonia,	with	that	replacement	being	more	pronounced	year-to-year	as	more	as	more	and	more	young	children	are	protected	by	the	vaccine	[5].	Further	work	is	needed	to	better	understand	the	impact	of	PCV13	on	the	epidemiology	of	S.	pneumonia	(including	serotype	replacement	in	the	elderly	population)	and	related	mortality	in	Russia.		Our	paper	has	some	limitations.	We	only	had	access	to	monthly	mortality	data;	moreover,	those	data	are	operational,	with	some	delays	in	reporting,	and	some	unreported	deaths	during	a	given	calendar	year	being	reported	for	January	of	the	next	year	[15].	Moreover	those	data	were	made	available	after	the	start	of	the	study	period	[15],	with	the	earlier	data	extracted	retrospectively.	Influenza	surveillance	data	can	also	be	subject	to	noise	such	as	the	discrepancy	between	the	timing	of	specimen	collection	and	testing/reporting.	For	the	2013/14	season,	influenza	circulation	was	still	significant	by	week	20	of	2014,	with	18%	of	respiratory	specimens	testing	positive	for	influenza	during	that	week	[11];	however,	no	surveillance	data	for	the	subsequent	weeks	during	that	season	are	available	in	[11].	All	of	this	might	explain	some	lack	of	temporal	consistency	in	the	model	fit	(Figure	2),	particularly	during	the	early	part	of	the	study	period	when	the	quality	of	the	data	may	be	more	questionable.	Finer	mortality	data	stratified	by	week/age	group	are	needed	to	get	a	more	comprehensive	understanding	of	decline	in	the	rates	of	respiratory	mortality	no	associated	with	influenza	in	the	period	following	the	introduction	of	PCV13	in	Russia.		We	believe	that	despite	the	above	limitations,	our	results	suggest	a	robust	decline	the	rates	of	respiratory	mortality	not	associated	with	influenza	following	the	introduction	of	PCV13	in	Russia.	That	decline	is	consistent	with	replacement	of	vaccine	serotypes	of	S.	pneumoniae	that	are	more	drug-resistant	compared	to	non-vaccine	serotypes	in	Russia.	Further	work	is	needed	to	better	understand	the	impact	
of	PCV13	on	the	epidemiology	of	S.	pneumonia	and	related	severe	outcomes,	including	mortality	in	Russia.				
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